Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 8/20 | 0.69 |
| ▸ | NOS1 | P29475 | 8/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.69 |
| ▸ | HTR1D | P28221 | 10/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | HTR1E | P28566 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12367651 | 0.93 | NOS3 (0.62) | NOS3NOS1SLC6A2HTR1DNOS2 | |
| SCHEMBL2264612 | 0.93 | NOS3 (0.62) | NOS3NOS1SLC6A2HTR1DNOS2 | |
| SCHEMBL1122317 | 0.90 | NOS3 (0.67) | NOS3NOS1SLC6A2HTR1DNOS2 | |
| SCHEMBL12621060 | 0.90 | NOS3 (0.67) | NOS3NOS1SLC6A2HTR1DNOS2 | |
| SCHEMBL13850013 | 0.88 | NOS3 (0.53) | NOS3NOS1SLC6A2HTR1DNOS2 | |
| SCHEMBL12305088 | 0.87 | NOS3 (0.53) | NOS3NOS1SLC6A2HTR1DNOS2 | |
| SCHEMBL12367706 | 0.86 | NOS3 (0.54) | NOS3NOS1SLC6A2HTR1DNOS2 | |
| SCHEMBL12621064 | 0.84 | NOS3 (0.66) | NOS3NOS1SLC6A2NOS2 | |
| SCHEMBL1121973 | 0.84 | NOS3 (0.66) | NOS3NOS1SLC6A2NOS2 | |
| SCHEMBL13850668 | 0.84 | NOS3 (0.53) | NOS3NOS1SLC6A2NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009062318-A1 | 3,5-SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131503-A1 | 3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | NEURAXON, INC (CA) | 2009-05-21 | — | — | US | disclosed |
| US-20090131503-A1 | 3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | NEURAXON, INC (CA) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131503-A1 | 3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | SLC6A2, AANAT, NOS3 | NOS3 3/4885NOS1 5/4885SLC6A2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.